MGMT and central nervous system cancer: To examine the association between ARPC5 expression and glioma prognosis in detail, we divided the glioma patients into different groups through different molecular subtypes for grade (WHO 2, WHO 3), gender (female, male), age (age ≤ 41, age > 41), IDH (mutant, wild type), 1p/19q (codel, non-codel), and MGMT (methylated, un-methylated) status (Fig. 2E-P).